Dear Sir, Edwards and Bloom righteously point out that it is experimentally difficult to prove an incretin role for glucagon-like peptide 1 (GLP-1) in humans. They argue that it is more important to judge a therapeutic (ªantidiabetogenicº) potential than to elucidate the underlying mechanism or to assess incretin functions. This is, from a pharmacotherapeutic point of view, true. There is, however, a basic scientific interest in elucidating the physiological role of gut hormones like gastric inhibitory polypeptide (GIP) and GLP-1, which together contribute approximately 50 % of the insulin response after an oral glucose load [1, 2] . Therefore, there is no doubt about an important incretin effect, and it is my guess that GIP is much more of an incretin than GLP-1. Unfortunately, GIP has little if any effects in Type II (non-insulin-dependent) diabetic patients [3, 4] . On the other hand, the interest that GLP-1 has received as a potential new treatment for Type II diabetes does not necessarily derive from the function that GLP-1 has in a healthy organism. Dismissing GLP-1 as an incretin hormone does not invalidate the therapeutic trials that are coming up with promising analogues.
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There is one aspect where I have a different view: Edwards and Bloom mention ªthe impossibility of assessment of the incretin effectº and use the multiplicity of actions of GLP-1 to explain why blocking one GLP-1 action leads to secondary changes in other variables (e. g. the acceleration of gastric emptying leads to an enhanced insulin and glucagon response due to a more rapid absorption of nutrients), which in turn might affect plasma glucose independently of any direct effects of GLP-1. While this is true and would require a great number of control experiments (e. g. intraduodenal instead of oral delivery of nutrients, ªclampingº of glycaemic concentrations etc.) for clarification, I still would like to know the overall effect of injecting GLP-1 [5] or of blocking its actions [6] to judge a net action profile.
GLP-1 is of much more interest as a potential pharmacological agent [7] . Its physiological and pathophysiological role in normal humans and several diseased states (impaired glucose tolerance and Type II diabetes, reactive hypoglycaemia, malassimilation, and others), however, still deserves attention. It appears too early to give up on these issues.
Yours sincerely, M. Nauck, MD
